Early-Onset Neonatal Sepsis: Evidence-Based Strategies for the Clinician

Recent Trends in Diagnosis and Management

In the last several years, clinicians have shifted from categorical risk-factor-based algorithms toward multivariate risk assessment models for early-onset neonatal sepsis (EONS). Neonatal intensive care units have increasingly adopted serial physical examination and laboratory screening—such as the serial neonatal sepsis calculator—to reduce unnecessary antibiotic exposure without missing true infections. Large retrospective cohorts now inform updated guidelines that emphasize the role of clinical trajectory over a single laboratory cutoff.

Background: Pathophysiology and Epidemiology

Early-onset neonatal sepsis, typically defined as culture-confirmed bacteremia or meningitis occurring within the first 72 hours of life, remains a leading cause of neonatal morbidity. Group B Streptococcus (GBS) Escherichia coli account for the majority of cases in term and preterm infants. Intrapartum antibiotic prophylaxis has significantly lowered the incidence of GBS disease, but non-GBS organisms and late-preterm neonates still present diagnostic challenges. The overall incidence ranges from 0.5 to 2 per 1,000 live births, with higher rates in very low birth weight infants.

User Concerns Among Neonatal Clinicians

• Overtreatment vs. undertreatment: Many clinicians worry about the risks of prolonged empiric antibiotics (necrotizing enterocolitis, dysbiosis, candidemia) versus the potential for missed sepsis.
• Integration of risk calculators: Adoption varies by institution, and some clinicians cite workflow barriers or skepticism about calculator performance in late-preterm and low-risk populations.
• Interpretation of negative cultures: Decision to stop antibiotics after 36–48 hours remains debated, especially when inflammatory markers are persistently elevated or the clinical picture is ambiguous.
• Resource variability: Access to rapid molecular diagnostics (e.g., multiplex PCR panels) is not universal, and clinicians must balance cost, turnaround time, and clinical impact.

Likely Impact on Clinical Practice

• Wider adoption of serial clinical assessment: More nurseries will likely transition from a “rule-out” approach to a “watch-and-wait” strategy for asymptomatic infants with risk factors, reducing antibiotic days.
• Refined antibiotic stewardship protocols: Expect further stratification by gestational age, maternal chorioamnionitis status, and postnatal clinical status, with shorter empiric courses when cultures remain negative.
• Increased use of adjunctive biomarkers: Serial C-reactive protein, procalcitonin, or newer markers (e.g., presepsin) may become routine to guide duration of therapy.
• Greater attention to long-term outcomes: Studies linking early antibiotic exposure to childhood conditions (asthma, obesity, atopy) may strengthen the impetus for judicious use.

What to Watch Next

• Machine learning models: Real-time clinical decision support tools that incorporate electronic health record data (maternal history, vital sign trends, lab values) are being piloted. Their external validity and impact on antibiotic days will be key.
• Point-of-care molecular diagnostics: Rapid (<1 hour) PCR-based panels for common neonatal pathogens could supplant routine blood cultures in some settings, but cost-effectiveness and impact on antimicrobial stewardship remain under evaluation.
• Updated CDC and AAP guidance: Revised recommendations for intrapartum antibiotic prophylaxis and postnatal management are anticipated within the next couple of years, incorporating data from large observational cohorts.
• Research on maternal interventions: Vaccines against GBS and novel approaches to prevent maternal colonization may alter the epidemiology of EONS over the next decade.